This publication summarizes the Pneumococcal Conjugate Vaccine (PCV) strategic demand forecasting completed in the first quarter of 2017. The forecast considers all AMC-eligible demand from countries that introduce with Gavi support, countries that transition to fully self-financing following Gavi support, and countries that introduce independent of Gavi support.

The forecasted demand assumes a 3-dose course administered through routine immunization programmes. The demand incorporates volumes for buffer stocks and wastage.

Major changes versus the forecast published in August 2012 (“version 5.0”), include the following:

- Forecast updated to use the most recent WHO/UNICEF coverage estimates and UN population projections. Additional information sources, e.g. shipment history for existing programmes, were also considered in the forecast of each country’s demand.
- India to begin phased introduction in 2017, versus 2016 assumed in version 5.0
- For the other 14 remaining potential introductions in the Gavi 73, forecasted introductions are generally 2 to 5 years later than assumed in version 5.0
- Switches to 4-dose vial presentations included.

**Disclaimer:** Except for countries which have already applied to Gavi for support for introduction of Pneumococcal Vaccines or are in the process of doing so, this forecast reflects the best possible estimates on countries’ expected time of introduction. The forecasted timeline for future introductions is not subject to approval by country representatives and, as such, does not constitute any commitment or obligation for any of the countries.
Forecasted Demand by Gavi Support Status for the 73 AMC-eligible Countries

Forecasted Demand and Contracted Volumes for 73 AMC-eligible Countries

Note: contracted volumes is based on the AMC Supply Agreements signed in March 2010, December 2011 and July 2013. [http://www.gavi.org/funding/pneumococcal-amc/manufacturers/supply-agreements/](http://www.gavi.org/funding/pneumococcal-amc/manufacturers/supply-agreements/)

For information related to the AMC: amc@gavi.org
For information related to the Pneumococcal Conjugate Vaccine Forecast: forecast@gavi.org